Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequence of irinotecan + cetuximab vs FOLFOX-4 as second-line therapy in metastatic colorectal cancer after FOLFIRI + bevacizumab
2007-006254-26Phase 3Active
- Sponsor
- Fondazione Giscad per la Ricerca sui Tumori
- Start
- Feb 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cetuximab, irinotecan and oxaliplatin in metastatic colorectal adenocarcinoma (mCRC) (2 arms), sponsored by Fondazione Giscad per la Ricerca sui Tumori. Primary endpoints: overall survival and activity. Started Feb 2008; status: active.
02
Drugs
cetuximabirinotecanoxaliplatin
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2007-006254-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-006254-26.